Cross-ancestry genome-wide association study defines the extended CYP2D6 locus as the principal genetic determinant of endoxifen plasma concentrations
Cross-ancestry genome-wide association study defines the extended CYP2D6 locus as the principal genetic determinant of endoxifen plasma concentrations
The therapeutic efficacy of tamoxifen is predominantly mediated by its active metabolites 4-hydroxy-tamoxifen and endoxifen, whose formation is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6). Yet, known CYP2D6 polymorphisms only partially determine metabolite concentrations in vivo. We performed the first cross-ancestry genome-wide association study with well-characterized patients of European, Middle-Eastern, and Asian descent (N = 497) to identify genetic factors impacting active and parent metabolite formation. Genome-wide significant variants were functionally evaluated in an independent liver cohort (N = 149) and in silico. Metabolite prediction models were validated in two independent European breast cancer cohorts (N = 287, N = 189). Within a single 1-megabase (Mb) region of chromosome 22q13 encompassing the CYP2D6 gene, 589 variants were significantly associated with tamoxifen metabolite concentrations, particularly endoxifen and metabolic ratio (MR) endoxifen/N-desmethyltamoxifen (minimal P = 5.4E-35 and 2.5E-65, respectively). Previously suggested other loci were not confirmed. Functional analyses revealed 66% of associated, mostly intergenic variants to be significantly correlated with hepatic CYP2D6 activity or expression (ρ = 0.35 to -0.52), and six hotspot regions in the extended 22q13 locus impacting gene regulatory function. Machine learning models based on hotspot variants (N = 12) plus CYP2D6 activity score (AS) increased the explained variability (~ 9%) compared with AS alone, explaining up to 49% (median R2 ) and 72% of the variability in endoxifen and MR endoxifen/N-desmethyltamoxifen, respectively. Our findings suggest that the extended CYP2D6 locus at 22q13 is the principal genetic determinant of endoxifen plasma concentration. Long-distance haplotypes connecting CYP2D6 with adjacent regulatory sites and nongenetic factors may account for the unexplained portion of variability.
712-723
Khor, Chiea Chuen
0083aa0e-fb34-48d0-ada6-05617747b6cb
Winter, Stefan
9735df20-413a-448f-abca-088bfba333db
Sutiman, Natalia
afc42605-aac5-474f-a857-d73b3e223e0f
Mürdter, Thomas E
37a5629c-2337-4438-ac96-b8f52d71fa90
Chen, Sylvia
d8bd10d7-7ee1-47f5-87bb-61afeca0d300
Lim, Joanne Siok Liu
9329c38f-dc77-4312-9999-65087985074c
Li, Zheng
f520b115-b06a-47c7-8e81-cd123d8f28ae
Li, Jingmei
ce89f404-edac-4b9a-ba7f-f83d19b68be8
Sim, Kar Seng
0018f108-4956-43f9-985f-2c57c031091c
Ganchev, Boian
4a00fe3b-f7d8-4284-aa21-9103737fd38a
Eccles, Diana
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Eccles, Bryony
57ff1cdf-577d-421d-8f35-b12b8d1c2030
Tapper, William
9d5ddc92-a8dd-4c78-ac67-c5867b62724c
Zgheib, Nathalie K
8e475bd7-67b9-4279-a0ab-305a07388bcd
Tfayli, Arafat
02bb88ef-52be-4e68-8425-baef82009b8d
Ng, Raymond Chee Hui
b7d0f97b-c8a5-44e0-ba81-e8201296360a
Yap, Yoon Sim
0f64782d-12cf-4a51-a92d-6035c1842bb4
Lim, Elaine
69bfb7d1-dd99-4876-af94-da3394b0bf22
Wong, Mabel
cea7c516-dce0-4d75-af0e-8dd604724560
Wong, Nan Soon
bca5b194-1f7a-48f1-815d-a33243878a31
Ang, Peter Cher Siang
ca114ed3-8f9a-4250-abf0-89c70057324b
Dent, Rebecca
9eb8ede0-9cd6-4fb7-885c-e8b582b80221
Tremmel, Roman
7899ff06-afae-45a2-9e02-2e280f1b8de2
Klein, Kathrin
fa619e7d-4d70-44de-8ed0-05d898e89c44
Schaeffeler, Elke
9793108f-2d1d-4ef9-b0fb-b942ccfc2816
Zhou, Yitian
e27c0cea-cdd1-465f-9a7e-c3a5117c56ff
Lauschke, Volker M
db75a2a0-07b7-490e-8667-899feafd17df
Eichelbaum, Michel
201164a8-e3b7-4cbb-8ac2-ba8f905106eb
Schwab, Matthias
16ef1f40-d7c6-4136-b595-3812b3c54cf7
Brauch, Hiltrud B
2f4c2277-b1cd-4f43-8c5b-ffce6a55f4af
Chowbay, Balram
a017dcbf-9ee7-4f82-a947-281eef5ce11e
Schroth, Werner
904eedff-4532-4d67-9b1d-7e2335e021f3
March 2023
Khor, Chiea Chuen
0083aa0e-fb34-48d0-ada6-05617747b6cb
Winter, Stefan
9735df20-413a-448f-abca-088bfba333db
Sutiman, Natalia
afc42605-aac5-474f-a857-d73b3e223e0f
Mürdter, Thomas E
37a5629c-2337-4438-ac96-b8f52d71fa90
Chen, Sylvia
d8bd10d7-7ee1-47f5-87bb-61afeca0d300
Lim, Joanne Siok Liu
9329c38f-dc77-4312-9999-65087985074c
Li, Zheng
f520b115-b06a-47c7-8e81-cd123d8f28ae
Li, Jingmei
ce89f404-edac-4b9a-ba7f-f83d19b68be8
Sim, Kar Seng
0018f108-4956-43f9-985f-2c57c031091c
Ganchev, Boian
4a00fe3b-f7d8-4284-aa21-9103737fd38a
Eccles, Diana
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Eccles, Bryony
57ff1cdf-577d-421d-8f35-b12b8d1c2030
Tapper, William
9d5ddc92-a8dd-4c78-ac67-c5867b62724c
Zgheib, Nathalie K
8e475bd7-67b9-4279-a0ab-305a07388bcd
Tfayli, Arafat
02bb88ef-52be-4e68-8425-baef82009b8d
Ng, Raymond Chee Hui
b7d0f97b-c8a5-44e0-ba81-e8201296360a
Yap, Yoon Sim
0f64782d-12cf-4a51-a92d-6035c1842bb4
Lim, Elaine
69bfb7d1-dd99-4876-af94-da3394b0bf22
Wong, Mabel
cea7c516-dce0-4d75-af0e-8dd604724560
Wong, Nan Soon
bca5b194-1f7a-48f1-815d-a33243878a31
Ang, Peter Cher Siang
ca114ed3-8f9a-4250-abf0-89c70057324b
Dent, Rebecca
9eb8ede0-9cd6-4fb7-885c-e8b582b80221
Tremmel, Roman
7899ff06-afae-45a2-9e02-2e280f1b8de2
Klein, Kathrin
fa619e7d-4d70-44de-8ed0-05d898e89c44
Schaeffeler, Elke
9793108f-2d1d-4ef9-b0fb-b942ccfc2816
Zhou, Yitian
e27c0cea-cdd1-465f-9a7e-c3a5117c56ff
Lauschke, Volker M
db75a2a0-07b7-490e-8667-899feafd17df
Eichelbaum, Michel
201164a8-e3b7-4cbb-8ac2-ba8f905106eb
Schwab, Matthias
16ef1f40-d7c6-4136-b595-3812b3c54cf7
Brauch, Hiltrud B
2f4c2277-b1cd-4f43-8c5b-ffce6a55f4af
Chowbay, Balram
a017dcbf-9ee7-4f82-a947-281eef5ce11e
Schroth, Werner
904eedff-4532-4d67-9b1d-7e2335e021f3
Khor, Chiea Chuen, Winter, Stefan, Sutiman, Natalia, Mürdter, Thomas E, Chen, Sylvia, Lim, Joanne Siok Liu, Li, Zheng, Li, Jingmei, Sim, Kar Seng, Ganchev, Boian, Eccles, Diana, Eccles, Bryony, Tapper, William, Zgheib, Nathalie K, Tfayli, Arafat, Ng, Raymond Chee Hui, Yap, Yoon Sim, Lim, Elaine, Wong, Mabel, Wong, Nan Soon, Ang, Peter Cher Siang, Dent, Rebecca, Tremmel, Roman, Klein, Kathrin, Schaeffeler, Elke, Zhou, Yitian, Lauschke, Volker M, Eichelbaum, Michel, Schwab, Matthias, Brauch, Hiltrud B, Chowbay, Balram and Schroth, Werner
(2023)
Cross-ancestry genome-wide association study defines the extended CYP2D6 locus as the principal genetic determinant of endoxifen plasma concentrations.
Clinical Pharmacology and Therapeutics, 113 (3), .
(doi:10.1002/cpt.2846).
Abstract
The therapeutic efficacy of tamoxifen is predominantly mediated by its active metabolites 4-hydroxy-tamoxifen and endoxifen, whose formation is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6). Yet, known CYP2D6 polymorphisms only partially determine metabolite concentrations in vivo. We performed the first cross-ancestry genome-wide association study with well-characterized patients of European, Middle-Eastern, and Asian descent (N = 497) to identify genetic factors impacting active and parent metabolite formation. Genome-wide significant variants were functionally evaluated in an independent liver cohort (N = 149) and in silico. Metabolite prediction models were validated in two independent European breast cancer cohorts (N = 287, N = 189). Within a single 1-megabase (Mb) region of chromosome 22q13 encompassing the CYP2D6 gene, 589 variants were significantly associated with tamoxifen metabolite concentrations, particularly endoxifen and metabolic ratio (MR) endoxifen/N-desmethyltamoxifen (minimal P = 5.4E-35 and 2.5E-65, respectively). Previously suggested other loci were not confirmed. Functional analyses revealed 66% of associated, mostly intergenic variants to be significantly correlated with hepatic CYP2D6 activity or expression (ρ = 0.35 to -0.52), and six hotspot regions in the extended 22q13 locus impacting gene regulatory function. Machine learning models based on hotspot variants (N = 12) plus CYP2D6 activity score (AS) increased the explained variability (~ 9%) compared with AS alone, explaining up to 49% (median R2 ) and 72% of the variability in endoxifen and MR endoxifen/N-desmethyltamoxifen, respectively. Our findings suggest that the extended CYP2D6 locus at 22q13 is the principal genetic determinant of endoxifen plasma concentration. Long-distance haplotypes connecting CYP2D6 with adjacent regulatory sites and nongenetic factors may account for the unexplained portion of variability.
Text
Clin Pharma and Therapeutics - 2023 - Khor - Cross‐Ancestry Genome‐Wide Association Study Defines the Extended CYP2D6 Locus
- Version of Record
More information
Accepted/In Press date: 23 December 2022
e-pub ahead of print date: 11 January 2023
Published date: March 2023
Additional Information:
Funding Information:
This study was supported by the National Medical Research Council Singapore (NMRC/1159/2008, NMRCB1011, NRFCG1516, NMRCG13163, NMRC/CIRG/1423/2015 and MOH‐000377) grants and the National Research Foundation of Singapore grants (NRF‐NRFI2018‐01 and NRF‐NRFF2017‐02). Additional funding was provided by the Biomedical Research Council, Agency for Science, Technology and Research, Singapore and the Horizon 2020‐PHC‐2015 grant U‐PGx 668353. German funding resources include: Robert Bosch Foundation, Stuttgart, Germany, German Federal Ministry of Education and Research (BMBF 01ZP0502); the German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, 72074 Tübingen, Germany, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy‐EXC 2180‐390900677 and EXC 2064/1‐390727645 as well as the DFG grants SCHR 1323/2‐1 and MU 1727/2‐1, and the Interfaculty Center for Pharmacogenomics and Drug Research (ICEPHA) University of Tübingen.
Funding Information:
This study was supported by the National Medical Research Council Singapore (NMRC/1159/2008, NMRCB1011, NRFCG1516, NMRCG13163, NMRC/CIRG/1423/2015 and MOH-000377) grants and the National Research Foundation of Singapore grants (NRF-NRFI2018-01 and NRF-NRFF2017-02). Additional funding was provided by the Biomedical Research Council, Agency for Science, Technology and Research, Singapore and the Horizon 2020-PHC-2015 grant U-PGx 668353. German funding resources include: Robert Bosch Foundation, Stuttgart, Germany, German Federal Ministry of Education and Research (BMBF 01ZP0502); the German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, 72074 Tübingen, Germany, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy-EXC 2180-390900677 and EXC 2064/1-390727645 as well as the DFG grants SCHR 1323/2-1 and MU 1727/2-1, and the Interfaculty Center for Pharmacogenomics and Drug Research (ICEPHA) University of Tübingen. Open Access funding enabled and organized by Projekt DEAL.
Publisher Copyright:
© 2023 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Identifiers
Local EPrints ID: 475204
URI: http://eprints.soton.ac.uk/id/eprint/475204
ISSN: 0009-9236
PURE UUID: 40edd222-c37a-4afa-9754-91006e3c1ef1
Catalogue record
Date deposited: 14 Mar 2023 17:33
Last modified: 17 Mar 2024 02:49
Export record
Altmetrics
Contributors
Author:
Chiea Chuen Khor
Author:
Stefan Winter
Author:
Natalia Sutiman
Author:
Thomas E Mürdter
Author:
Sylvia Chen
Author:
Joanne Siok Liu Lim
Author:
Zheng Li
Author:
Jingmei Li
Author:
Kar Seng Sim
Author:
Boian Ganchev
Author:
Bryony Eccles
Author:
Nathalie K Zgheib
Author:
Arafat Tfayli
Author:
Raymond Chee Hui Ng
Author:
Yoon Sim Yap
Author:
Elaine Lim
Author:
Mabel Wong
Author:
Nan Soon Wong
Author:
Peter Cher Siang Ang
Author:
Rebecca Dent
Author:
Roman Tremmel
Author:
Kathrin Klein
Author:
Elke Schaeffeler
Author:
Yitian Zhou
Author:
Volker M Lauschke
Author:
Michel Eichelbaum
Author:
Matthias Schwab
Author:
Hiltrud B Brauch
Author:
Balram Chowbay
Author:
Werner Schroth
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
